Thyroid tumor
Conditions
Interventions
The experimental group:In the experimental group, mitoxantrone hydrochloride was used as a tracer for lymph node staining during radical thyroid cancer surgery.
The control group:In the control group, carbon nanoparticles were used for lymph node staining and tracing during radical thyroid cancer surgery.
The blank group:In the blank group, an equivalent volume of normal saline was injected during radical thyroid cancer surgery.
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1.The patients were aged between 18 and 69 years.2.All patients were preoperatively evaluated using ultrasound elastography and fine-needle aspiration cytology, and subsequently confirmed by postoperative histopathological examination to have bilateral papillary or follicular thyroid carcinoma.3.Comprehensive clinicopathological data were obtained either preoperatively or during follow-up, including preoperative serum calcium levels, parathyroid hormone (PTH) levels, histological tumor grading, tumor size, and the number of tumor foci.4.None of the patients received anti-tumor therapies such as radiofrequency ablation, microwave ablation, percutaneous ethanol injection, chemotherapy, or targeted therapy prior to surgery.5.All patients underwent their first surgical procedure.6.Preoperative serum calcium and parathyroid hormone levels were within normal limits.7.Patients were conscious, hemodynamically stable, and able to cooperate independently in completing scale-based assessments.8.Patients demonstrated good compliance, had no psychiatric disorders or consciousness disturbances, and were able to adhere to regular follow-up examinations.
Exclusion criteria
Exclusion criteria: 1.Patients with various advanced-stage metabolic disorders.2.Patients with symptomatic cerebrovascular or peripheral vascular disease.3.Patients with concomitant distant metastases.4.Patients with an expected survival time of less than 6 months.5.Patients with known hypersensitivity or contraindications to mitoxantrone hydrochloride or nano-carbon.6.Patients with severe cardiac, hepatic, or renal dysfunction, coagulation disorders, or significant neurological impairment.7.Patients with a history of malignancies other than thyroid carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of lymph node dissection;Traceability effect evaluation;Parathyroid gland recognition and the situation of accidental resection or injury;Evaluation of surgical field clarity;Calcium level;PTH level;Perioperative related complications;Lymph node metastasis rate; | — |
Countries
China
Contacts
Public ContactYu Cheng
Tianjin First Central Hospital
Outcome results
None listed